The FDA cleared Novo Nordisk’s 7.2mg Wegovy HD in 54 days flat. Filing to approval in under two months. The fourth product to move through the Commissioner’s National Priority Voucher program, which fast-tracks applications for therapies tied to national health priorities.
Clinical data backed the label: the higher dose delivered greater average weight reduction than previously approved doses, with a safety profile consistent with what’s already known about semaglutide. In patients with both obesity and type 2 diabetes, the higher dose offered similar hemoglobin A1C reduction compared to lower doses. GI side effects remain the most common complaints. One new wrinkle worth watching — altered skin sensation, including burning and pain, showed up more frequently at 7.2mg, though it generally resolved on its own or with dose reduction, and is still under active FDA investigation.
For Novo Nordisk, this isn’t just a label update. Wegovy faces real competition from Eli Lilly’s tirzepatide, and superior weight-loss outcomes on a package insert shift prescriber behavior. A higher-efficacy dose keeps patients from migrating and gives sales reps a stronger clinical argument. The GLP-1 market doesn’t reward second place.
The FDA’s existing boxed warning for thyroid C-cell tumors carries over. A public hearing on the CNPV pilot is scheduled for June.